PTO Rejects Gilead's Patents For HIV Drug

The U.S. Patent and Trademark Office has rejected Gilead Sciences Inc.'s four patents related to HIV/AIDS medication, finding that the company neglected to cite prior art when securing the patents....

Already a subscriber? Click here to view full article